BORJE S ANDERSSON to Leukemia
This is a "connection" page, showing publications BORJE S ANDERSSON has written about Leukemia.
Connection Strength
0.611
-
Fatal pulmonary failure complicating high-dose cytosine arabinoside therapy in acute leukemia. Cancer. 1990 Mar 01; 65(5):1079-84.
Score: 0.048
-
Allogeneic stem cell transplantation for myelofibrosis with leukemic transformation. Biol Blood Marrow Transplant. 2010 Apr; 16(4):555-9.
Score: 0.047
-
Sensitivity and resistance to chemotherapy in acute leukemia: correlation with in vitro drug uptake and lack of potentiation by verapamil. Med Oncol Tumor Pharmacother. 1987; 4(1):17-21.
Score: 0.038
-
Subacute pulmonary failure complicating therapy with high-dose Ara-C in acute leukemia. Cancer. 1985 Nov 01; 56(9):2181-4.
Score: 0.035
-
Tumor necrosis factor-alpha blockade for the treatment of acute GVHD. Blood. 2004 Aug 01; 104(3):649-54.
Score: 0.032
-
Long-term follow-up of a phase I study of high-dose decitabine, busulfan, and cyclophosphamide plus allogeneic transplantation for the treatment of patients with leukemias. Cancer. 2003 Mar 01; 97(5):1242-7.
Score: 0.029
-
Prednimustine and vincristine compared with cytosine arabinoside and thioguanine for treatment of elderly patients with acute nonlymphoblastic leukemia. Cancer Chemother Pharmacol. 1982; 9(2):89-92.
Score: 0.027
-
Decitabine with allogeneic peripheral blood stem cell transplantation in the therapy of leukemia relapse following a prior transplant: results of a phase I study. Bone Marrow Transplant. 2001 Jun; 27(12):1221-5.
Score: 0.026
-
Leukemic cell versus plasma levels of daunorubicin and daunorubicinol after infusion of daunorubicin as free drug or the DNA complex. Cancer Chemother Pharmacol. 1980; 4(3):205-7.
Score: 0.024
-
Liquid chromatographic monitoring of daunorubicin and daunorubicinol in plasma from leukemic patients treated with daunorubicin or the daunorubicin-DNA complex. Cancer Chemother Pharmacol. 1979; 2(1):15-7.
Score: 0.022
-
Allogeneic blood stem cell transplantation in advanced hematologic cancers. Bone Marrow Transplant. 1997 Mar; 19(5):455-60.
Score: 0.019
-
Allogeneic transplantation for advanced leukemia: improved short-term outcome with blood stem cell grafts and tacrolimus. Transplantation. 1996 Dec 27; 62(12):1806-10.
Score: 0.019
-
Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after matched unrelated donor marrow transplantation. Blood. 1996 Dec 01; 88(11):4383-9.
Score: 0.019
-
Impact of preexisting CNS involvement on the outcome of bone marrow transplantation in adult hematologic malignancies. J Clin Oncol. 1996 Nov; 14(11):3036-42.
Score: 0.019
-
Interferon-alpha and interleukin-2 as treatment for leukemia relapse after allogeneic bone marrow transplantation. Cytokines Mol Ther. 1995 Jun; 1(2):115-22.
Score: 0.017
-
Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: potential advantage of blood over marrow allografts. Blood. 1995 Mar 15; 85(6):1659-65.
Score: 0.017
-
Etoposide, cyclophosphamide, total-body irradiation, and allogeneic bone marrow transplantation for hematologic malignancies. J Clin Oncol. 1994 Sep; 12(9):1923-30.
Score: 0.016
-
Allogeneic bone marrow transplantation for hematological malignancies following etoposide, cyclophosphamide, and fractionated total body irradiation. Am J Hematol. 1992 Sep; 41(1):40-4.
Score: 0.014
-
An effective acute graft-vs.-host disease prophylaxis with minidose methotrexate, cyclosporine, and single-dose methylprednisolone. Am J Hematol. 1991 Dec; 38(4):288-92.
Score: 0.013
-
Leukemia-associated skin infiltrates. Postgrad Med. 1989 Feb 01; 85(2):45-50, 53.
Score: 0.011
-
The effects of acetaldophosphamide, a novel stable aldophosphamide analogue, on normal human and leukemic progenitor cells in vitro: implications for use in bone marrow purging. Cancer Res. 1988 Jan 15; 48(2):339-45.
Score: 0.010
-
Heterogeneity in acute undifferentiated leukemia. Hematol Pathol. 1988; 2(2):79-90.
Score: 0.010
-
Effect of 1-beta-D-arabinofuranosylcytosine (ara-C) on nuclear topoisomerase II activity and on the DNA cleavage and cytotoxicity produced by 4'-(9-acridinylamino)methanesulfon-m-anisidide (m-AMSA) and etoposide in m-AMSA-sensitive and -resistant human leukemia cells. Biochem Pharmacol. 1987 Dec 01; 36(23):4067-77.
Score: 0.010
-
Systemic aspergillosis as cause of myocardial infarction. Cancer. 1986 Nov 01; 58(9):2146-50.
Score: 0.009
-
Effects of 3'-deamino-3'-(3-cyano-4-morpholinyl)doxorubicin and doxorubicin on the survival, DNA integrity, and nucleolar morphology of human leukemia cells in vitro. Cancer Res. 1986 Aug; 46(8):4041-6.
Score: 0.009
-
Drug sensitivity and cross-resistance of the 4'-(9-acridinylamino)methanesulfon-m-anisidide-resistant subline of HL-60 human leukemia. Cancer Res. 1986 Jul; 46(7):3330-3.
Score: 0.009
-
Evolution of clinical studies with high-dose cytosine arabinoside at the M.D. Anderson Hospital. Semin Oncol. 1985 Jun; 12(2 Suppl 3):98-104.
Score: 0.009
-
Possible mechanisms of immunotherapy action in acute nonlymphocytic leukemia: macrophage production of colony-stimulating activity. Recent Results Cancer Res. 1982; 80:64-9.
Score: 0.007
-
Glucocorticoid receptor concentrations and terminal transferase activity as indicators of prognosis in acute non-lymphocytic leukaemia. Br Med J (Clin Res Ed). 1981 Jun 06; 282(6279):1826-9.
Score: 0.007
-
Pharmacokinetics of daunorubicin after administration as free drug or as DNA complex in leukemic patients. Cancer Chemother Pharmacol. 1981; 5(4):261-6.
Score: 0.006
-
Biochemical markers as indicators of prognosis in acute nonlymphocytic leukemia (ANLL). Adv Enzyme Regul. 1980; 19:287-93.
Score: 0.006
-
Long-term outcome of a phase II study of BM transplants, partially depleted ex-vivo of CD5-positive and CD8-positive T-lymphocytes in unrelated and related donor 1 antigen mismatched recipients. Cytotherapy. 1999; 1(5):401-7.
Score: 0.005
-
Liquid chromatographic determination of daunorubicin and daunorubicinol in plasma from leukemic patients. J Chromatogr. 1978 Jun 01; 153(1):211-8.
Score: 0.005
-
The impact of T-cell depletion on the effects of HLA DR beta 1 and DQ beta allele matching in HLA serologically identical unrelated donor bone marrow transplantation. Biol Blood Marrow Transplant. 1997 Jun; 3(2):76-82.
Score: 0.005
-
A phase I-II study of high-dose thiotepa, busulfan and cyclophosphamide as a preparative regimen for allogeneic marrow transplantation. Bone Marrow Transplant. 1994 Sep; 14(3):449-53.
Score: 0.004
-
Effectiveness of an oral triazole for opportunistic mold infections in patients with cancer: experience with SCH 39304. Clin Infect Dis. 1993 Dec; 17(6):1022-31.
Score: 0.004
-
Comparative studies on the in vitro killing of human normal and leukemic clonogenic cells (CFUc) by daunorubicin, daunorubicinol, and daunorubicin-DNA complex. Cancer Chemother Pharmacol. 1979; 2(1):19-24.
Score: 0.001